ArticleJournal of medicinal chemistry2026
Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Fabio AriasDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus Cartuja s/n, 18071 Granada, Spain.ORCID 0000-0002-9906-6450
Sumati RohillaDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Yudibeth Sixto-LópezDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus Cartuja s/n, 18071 Granada, Spain.ORCID 0000-0001-8903-3834
Koral S E RichardDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.ORCID 0009-0009-9076-3346
Sandeep DasDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.ORCID 0000-0002-6722-3909
Sumit K AnandDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Pilar Maria Luque-NavarroDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus Cartuja s/n, 18071 Granada, Spain.ORCID 0000-0003-0983-5322
Guillermo Bañuelos-SanchezDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus Cartuja s/n, 18071 Granada, Spain.
Juan Luis Pacheco-GarcíaDepartamento de Química Física e Instituto de Biotecnología, Universidad de Granada, Av. Fuentenueva s/n, 18071 Granada, Spain.ORCID 0000-0001-6043-7536
Reethika GadeDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
M Peyton McKinneyDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Dhananjay KumarDepartment of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Jemiah MaxieDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
W Rylan CorrDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Nilesh PandeyDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Harpreet KaurDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Jibin DingMetabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Lin TanMetabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
Elisha ScottDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Hyung NamDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Eyal GottliebMetabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States.
A Wayne OrrDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Nirav DhaneshaDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Arif YurdagulDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Angel L PeyUnidad de Excelencia en Química Aplicada a Biomedicina y Medioambiente, Universidad de Granada, Av. Fuentenueva s/n, 18071 Granada, Spain.
Francisco Franco-MontalbánDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus Cartuja s/n, 18071 Granada, Spain.ORCID 0000-0001-6539-1653
José A Gómez VidalDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus Cartuja s/n, 18071 Granada, Spain.ORCID 0000-0003-0937-698X
Oren RomDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana 71103, United States.
Mónica Díaz-GavilánDepartamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Universidad de Granada, Campus Cartuja s/n, 18071 Granada, Spain.ORCID 0000-0002-7868-7231
Funding
Nck Adaptor Proteins in Atherogenic Endothelial ActivationR01HL133497 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2016 to 2024
$3.8MDysregulations in Polyamine Metabolism During AtherosclerosisR01HL167758 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Arif Yurdagul · 2023 to 2026
$2.2MEphA2 regulation of atherosclerotic smooth muscle phenotypeR01HL173972 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Anthony Wayne Orr · 2024 to 2026
$2.1MLipidated Amino Acids in Cardiometabolic DiseasesR01DK134011 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Oren Rom · 2022 to 2026
$2.1MDysregulated Oxalate Metabolism in Cardiometabolic DiseasesR01DK136685 · NIDDK · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Oren Rom · 2023 to 2026
$1.7MNutrient Sensing of Apoptotic Cells by Macrophages Resolves Inflammation, Drives Atherosclerosis Regression, and Promotes Features of Plaque InstabilityR01HL180481 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI Arif Yurdagul · 2025 to 2026
$1.3MMechanisms of glycine-based therapy for atherosclerosisR00HL150233 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ROM, OREN SHALOM · 2021 to 2023
$747kProcessing of Apoptotic Cell-Derived Cargo by Macrophages Continues Efferocytosis and Drives Atherosclerosis RegressionR00HL145131 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI YURDAGUL, ARIF · 2021 to 2023
$747kMultidisciplinary Training in Cardiovascular PathophysiologyT32HL155022 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE, STOKES, KAREN Y · 2021 to 2025
$619kProcessing of Apoptotic Cell-Derived Cargo by Macrophages Continues Efferocytosis and Drives Atherosclerosis RegressionK99HL145131 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YURDAGUL, ARIF · 2019 to 2020
$335kMechanisms of glycine-based therapy for atherosclerosisK99HL150233 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROM, OREN SHALOM · 2020 to 2021
$207kNHLBI NIH HHS K99 HL145131NHLBI NIH HHS K99 HL150233NHLBI NIH HHS R00 HL145131NHLBI NIH HHS R00 HL150233NHLBI NIH HHS R01 HL133497NHLBI NIH HHS R01 HL167758NHLBI NIH HHS R01 HL173972NHLBI NIH HHS R01 HL180481NHLBI NIH HHS T32 HL155022NIDDK NIH HHS R01 DK134011NIDDK NIH HHS R01 DK136685
Abstract
Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder caused by hepatic oxalate overproduction due to alanine-glyoxylate aminotransferase (AGXT) deficiency. Therapeutic strategies targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), key enzymes in glyoxylate metabolism, have shown promise in reducing oxalate burden. However, recently approved siRNA therapies remain limited by high cost, unfavorable pharmacokinetics, and limited global accessibility. We report the development of compound
Indexed as
Alcohol OxidoreductasesEnzyme InhibitorsHyperoxaluria, PrimaryL-Lactate DehydrogenaseOxalatesAnimalsHepatocytesHumansMaleMiceMice, Inbred C57BLMice, KnockoutProteolysisTransaminasesAlanine-glyoxylate transaminaseAlcohol OxidoreductasesEnzyme Inhibitorsglycollate oxidaseL-Lactate DehydrogenaseOxalatesTransaminases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.